[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-459373-105":59,"doc-detail-459373-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","biomarkers-and-proteomics-in-amyloid-pet-negative-persons-with-clinical-signs-of-mci-or-mild-dementia","Biomarkers and proteomics in amyloid PET negative persons with clinical signs of MCI or mild dementia","","Background: Screening for clinical trials identifies persons with clinical symptoms of Mild Cognitive Impairment (MCI) or Alzheimer’s disease (AD) but no amyloid on PET. This study compared blood biomarkers and proteomics in such amyloid PET-negative screen failures with cognitively normal amyloid PET-negative participants and with amyloid PET-positive MCI or mild AD patients. Method: Bio-Hermes data from 296 amyloid PET-negative symptomatic participants, 313 cognitively normal amyloid-negative participants, and 258 amyloid PET-positive symptomatic participants were analyzed using PET, plasma Aβ, tau markers, NfL, GFAP, cytokines, and a 7596-protein panel. Conclusion: NfL suggested significant neurodegeneration; amyloid- and tau-related biomarkers and proteomics showed no specific abnormalities after adjustment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biomarkers-and-proteomics-in-amyloid-pet-negative-persons-with-clinical-signs-of-mci-or-mild-dementia/459373/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biomarkers-and-proteomics-in-amyloid-pet-negative-persons-with-clinical-signs-of-mci-or-mild-dementia/459373.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What groups were compared in the study?","Question",{"text":112,"@type":113},"Amyloid PET-negative persons with clinical signs of MCI or mild AD were compared with cognitively normal amyloid PET-negative participants and with amyloid PET-positive MCI or mild AD patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers showed a significant difference?",{"text":117,"@type":113},"NfL was higher in the symptomatic amyloid PET-negative group compared with the cognitively normal amyloid PET-negative group.",{"name":119,"@type":110,"acceptedAnswer":120},"What did proteomics reveal after statistical adjustment?",{"text":121,"@type":113},"After False Discovery Rate adjustment, no Somalogic proteins were significantly different between amyloid PET-negative symptomatic participants and cognitively normal amyloid PET-negative participants.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},459373,1790755801,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":39,"preview_page_count":81,"preview_urls":143},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10. 1002/alz70856_105032  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nBiomarkers and proteomics in amyloid PET negative persons with clinical signs of MCI or mild dementia  \nRichard Mohs1  Douglas W. Beauregard 1  Allan I. Levey2  Erik C. B. Johnson3  Jessie Nicodemus-Johnson4  Robin Wolz5  John Dwyer 1  \n1 Global Alzheimer’s Platform Foundation, Washington, DC, USA  \n2 Emory University School of Medicine, Atlanta, GA, USA  \n3 Goizueta Alzheimer’s Disease Research Center, Atlanta, GA, USA  \n4 Pentara Corporation, Salt Lake City, UT, USA  \n5 IXICO, London, London, United Kingdom  \nCorrespondence  \nRichard Mohs, Global Alzheimer’s Platform Foundation, Washington, DC, USA. [Email:](Email: mohsrichard@yahoo.com)[ mohsrichard@yahoo.com](Email: mohsrichard@yahoo.com)  \nAbstract  \nBackground: Screening for clinical trials identifies persons with clinical symptoms of Mild Cognitive Impairment (MCI) or Alzheimer’s disease (AD) but no amyloid on PET. We compared blood biomarkers and proteomics in these screen failures with cognitively normal, amyloid PET negative persons and with amyloid PET positive MCI or mild AD patients.  \nMethod: We analyzed data from 296 persons with clinical symptoms of MCI or mild AD from the Bio-Hermes study who were amyloid PET negative (MCI + AD AB-); we compared them with 313 Bio-Hermes participants who were cognitively normal and amyloid PET negative(CN AB-)and with258amyloid PET positive persons with clinical MCI or mild AD (MCI + AD AB+). Measures included regional amyloid PET, plasma A-beta40 and 42, total tau, p-tau 181, p-tau 217, NfL, GFAP, a panel of 69 cytokines (Fireplex) and 7596 proteins from the Somalogic panel.  \nResult: Relative to the CN AB- group, the MCI + AD AB- group were older, more cognitvely and functionally impaired, had slightly less education and were more likely to be non-white; the groups did not differ in gender or APOE4 rates. The groups did not differ on amyloid SUVR, p-tau 217, t-tau or GFAP. NfL was higher in MCI + AD ABpersons compared with CN AB-persons (Table 1 and 2). After using a False Discovery Rate adjustment there were no Somalogic proteins significantly different in MCI + AD AB-participants vs CNAB-participants. Several proteins were different in amyloid PET positive persons compared with amyloid PET negative parsons (Figure 1).  \nConclusion: NfL data indicate very significant neurodegeneration in symptomatic but amyloid PET negative clinical trial screen failures. Biomarkers reflecting amyloid and tau were not different and the proteomics profile did not find specific abnormalities in amyloid negative, symptomatic persons.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e105032.  \n[https://doi.org/10.1002/alz70856_105032](https://doi.org/10.1002/alz70856_105032)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of3  \nBIOMARKERS  \nBIOMARKERS","cbCairqQInsvM42c","https://ap.wps.com/l/cbCairqQInsvM42c","pdf",1072753,"English","# Abstract\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What groups were compared in the study?\",\"answer\":\"Amyloid PET-negative persons with clinical signs of MCI or mild AD were compared with cognitively normal amyloid PET-negative participants and with amyloid PET-positive MCI or mild AD patients.\"},{\"question\":\"Which biomarkers showed a significant difference?\",\"answer\":\"NfL was higher in the symptomatic amyloid PET-negative group compared with the cognitively normal amyloid PET-negative group.\"},{\"question\":\"What did proteomics reveal after statistical adjustment?\",\"answer\":\"After False Discovery Rate adjustment, no Somalogic proteins were significantly different between amyloid PET-negative symptomatic participants and cognitively normal amyloid PET-negative participants.\"}]","Biomarkers and proteomics in amyloid PET negative persons with clinical signs of MCI or mild dementia | PDF",[144,148,152],{"page_no":8,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/da7c45178e48b64eea73b3916207bef3.webp",983,1291,{"page_no":14,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/8a09b23be2cff00a4989083eff13fb8e.webp",982,1290,{"page_no":81,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/2fc5fe5e76d0aeabd4f365c9e62f5536.webp",981,1289]